— Recent developments of interest in cardiovascular medicine
The FDA approved the first RNA interference drug, patisiran (Onpattro), to treat adults with peripheral nerve disease from hereditary transthyretin-mediated amyloidosis -- a rare genetic disease characterized by a buildup of abnormal amyloid protein in peripheral nerves, the heart, and other organs. The list price is $450,000 per year, but a money-back guarantee is planned, STAT News reports.